LB54640
Total Payments
$140,328
Transactions
25
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $140,328 | 25 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $140,328 | 25 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity | Rhythm Pharmaceuticals, Inc. | $140,328 | 0 |
Top Doctors Receiving Payments for LB54640
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Aurora, CO | $140,328 | 25 |
Ad
Manufacturing Companies
- Rhythm Pharmaceuticals, Inc. $140,328
Product Information
- Type Drug
- Total Payments $140,328
- Total Doctors 0
- Transactions 25
About LB54640
LB54640 is a drug associated with $140,328 in payments to 0 healthcare providers, recorded across 25 transactions in the CMS Open Payments database. The primary manufacturer is Rhythm Pharmaceuticals, Inc..
Payment data is available from 2024 to 2024. In 2024, $140,328 was paid across 25 transactions to 0 doctors.
The most common payment nature for LB54640 is "Unspecified" ($140,328, 100.0% of total).
LB54640 is associated with 1 research study, including "A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity" ($140,328).